Use of 3D-printed freestanding structures for ex vivo tissue
The present disclosure provides information on the methodology used in the fabrication of three-dimensional cellularized tissue constructs from free-standing evacuable 3D printed composites and/or scaffolds embedded in an extracellular matrix mimic generated from biocompatible materials. The purposes of using these composite and/or scaffold materials is to generate complex embedded lumens that allow for complete perfusion of the matrix construct by standard cell culture media, thereby allowing for maintenance of large-scale 3D cell cultures in specific geometric forms. The use of biological extracellular matrix materials is to provide essential biological and mechanical signals needed to regulate the behavior of encapsulated cells. Furthermore, the methodology can be adapted such that the lumens generated are capable of being seeded with various endothelial and epithelial cell types as desired, thereby allowing for mimicry of in vivo vasculature, intestinal tracts, and other lumen-containing constructs. This disclosure provides the methodology for generating the tissue constructs.
1 . A method of generating cellularized ex vivo tissue constructs, the method comprising:
suspending a plurality of viable cells and/or a plurality of tissue fragments in a liquid-phase hydrogel to prepare a composite and/or solution;
encapsulating a free-standing evacuable filament structure within the composite and/or solution;
gelating the composite and/or solution to mimic an extracellular matrix; and
dissolving and evacuating the free-standing filament structure to create at least one lumen in the cellular matrix;
wherein:
the free-standing evacuable filament structure comprises a three-dimensionally printed free-standing structure;
the three-dimensionally printed free-standing structure comprises alginate and a pluronic blend;
the alginate and pluronic blend comprises about 10% to about 40% pluronic; and
the composite is dissolvable in an EDTA solvent or an equivalent thereof.
2 . The method of claim 1 , further comprising cross-linking the composite via submersion in a calcium chloride solution at a concentration between about 5 to about 250 mM.
3 . The method of claim 1 , further comprising depositing a base matrix layer on a substrate before inserting the structure, wherein a top layer of matrix is poured over the structure to ensure that the evacuable filament is embedded between two matrix layers.
4 . The method of claim 1 , wherein the composite and/or solution designed to mimic the extracellular matrix comprises at least one of matrigel, fibrin, gelatin, bovine collagen, porcine collagen, rat-tail collagen, gelatin methacrylate, alginate, decellularized extracellular matrix, or polyethylene glycol.
5 . The method of claim 4 , wherein the composite and/or solution designed to mimic the extracellular matrix comprises any combination of at least one of matrigel, fibrin, gelatin, bovine collagen, porcine collagen, rat-tail collagen, gelatin methacrylate, alginate, decellularized extracellular matrix, or polyethylene glycol.
6 . The method of claim 1 , wherein at least one lumen of the construct is perfused with cell growth media and the extracellular matrix binding proteins laminin and fibronectin are used to precoat an interior lumen of the construct following evacuation of the free-standing structure, but preceding an addition of endothelial or epithelial cell types to coat the interior lumen.
7 . The method of claim 1 , further comprising generating an in vitro model of a tumor directly via encapsulation and perfused sustenance of primary tumor cells or a carcinoma cell line within the matrix.
8 . The method of claim 1 , further comprising generating an ex vivo model of a tumor and perfused sustenance of excised tumor fragments within the matrix.
9 . The method of claim 1 , further comprising generating an in vitro model of highly dense vasculature via seeding of human or animal endothelial cells within one or more lumens, encapsulation of human or animal endothelial cells within the matrix, and addition of pro-angiogenic biomolecules or a gradient of pro-angiogenic biomolecules.
10 . The method of claim 1 , further comprising generating an in vitro model of a gut via seeding and sustenance of primary intestinal epithelial cells or an intestinal epithelial cell line within one or more lumens.
11 . The method of claim 1 , further comprising generating any additional organoid models via seeding and sustenance of primary somatic cells, cell lines, or primary stem cells either within a lumen or within the matrix.
12 . The method of claim 1 , further comprising exposing endothelial or epithelial cells within the constructs to physiological flow rates or specific flow rates, wherein the physiological flow rates or the specific flow rates optionally are 0.01-100 mL/min.
13 . The method of claim 1 , further comprising three-dimensionally coculturing multiple cell types or excised tissue in an environment that mimics extracellular matrix.
14 . The method of claim 1 , further comprising generating organoid-like structures from excised tissue or primary stem cells in specific geometries.
15 . The method of claim 1 , wherein the alginate and pluronic blend comprises F127 pluronic.